Overall signature of acquired KRAS gene changes in advanced non-small cell lung cancer patient with EGFR-TKI resistance.
Jie ZhengYuanyao DouDaijuan HuangYubo WangRui HanChen HuMengxiao ZhuConghua LuCaiyu LinDi WuYihui LiuHuan TangTingting HeWeilin JiangYong HePublished in: Japanese journal of clinical oncology (2023)
This study provides significant evidence of the role of acquired KRAS variants in the development of resistance to epidermal growth factor receptor-tyrosine kinase inhibitor therapy. Our results contribute to the growing body of knowledge on the mutational profiles associated with resistance to epidermal growth factor receptor-tyrosine kinase inhibitor treatment. Furthermore, our study highlights the KRAS gene change as a significant mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitor therapy.